Hepatitis C virus: Promising discoveries and new treatments

doi:10.3748/wjg.v22.i28.6393

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 28

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10047)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

949

WORD

364

HTML

6067

Tables (1-2)

266

Sum=7646

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

905

Download

1496

Sum=2401

Jul 28, 2016 (publication date) through Nov 18, 2024

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jul 28, 2016; 22(28): 6393-6401
Published online Jul 28, 2016. doi: 10.3748/wjg.v22.i28.6393

Table 1 Drugs for hepatitis C virus treatment

Mechanism of action	Drug	Genotype
Protease inhibitor	Telaprevir	1
	Boceprevir	1
	Simeprevir	1
	Paritaprevir	1, 4
	Grazoprevir	1, 4
	Asunaprevir¹	1
	ABT-450¹	1
	Faldaprevir¹	1
NS5A inhibitors	Daclatasvir	1, 3
	Ombitasvir	1, 4
	Ledipasvir	1, 4, 5, 6
	Elbasvir	1, 4
	Velpatasvir¹	4
NS5B inhibitors
Nucleotide-analogue	Sofosbuvir	1, 2, 3, 4, 5, 6
Non-nucleoside analogue	Dasabuvir	1
Non-nucleoside analogue	Beclabuvir¹	1

¹Non-FDA approved drugs.

Table 2 Treatments for hepatitis C virus infection

Ref.	Treatment, wk	Genotype	SVR (total, cirrhotic, non-cirrhotic)	Previously treated
Ref.	Treatment, wk	Genotype	SVR (total, cirrhotic, non-cirrhotic)	Patients included
Davis et al[53]	IFN, 24	1	3; NA; NA	Yes
Davis et al[53]	IFN + RBV, 24	1	30; NA; NA	Yes
IDEAL Study Team[54]	PEG-IFN/RBV, 48	1	39.8-40.9; 42.1-43.6; 20.7-23.6	No
ADVANCE Study Team[48]	TVR + PEG-IFN/RBV	1	75; 62-81; 62	No
REALIZE Study Team[49]	TVR + PEG-IFN/RBV, 48	1	63-64; 28-84; NA	Yes
SPRINT-2 Investigators[47]	BOC + PEG-IFN/RBV, 28	1	67; 70; 50	No
SPRINT-2 Investigators[47]	BOC + PEG-IFN/RBV, 48	1	68; 70; 50	No
RESPOND-2 Investigators[46]	BOC + PEG-IFN/RBV, 36	1	59; 35; 64	Yes
RESPOND-2 Investigators[46]	BOC + PEG-IFN/RBV, 48	1	66; 77; 66	Yes
PILLAR[55]	SMP + PEG-IFN/RBV, 12	1	80.5; NA; 80.5	No
PILLAR[55]	SMP + PEG-IFN/RBV, 24	1	86.1; NA; 86.1	No
Gane et al[56]	SOF + RBV, 12	2 or 3	100; NA; 100	No
Gane et al[56]	SOF + PEG-IFN/RBV, 8	2 or 3	100; NA; 100	No
COSMOS[57]	SMP + SOF + RBV, 24	1	NA; 93;79	Yes
	SMP + SOF, 24		NA; 93; 100
	SMP + SOF + RBV, 12		NA; 93; 93
	SMP + SOF, 12		NA; 90; 94
OPTIMIST-1[58]	SMP + SOF, 8	1	83; NA; 83	Yes
OPTIMIST-1[58]	SMP + SOF, 12	1	97; NA; 97	Yes
OPTIMIST-2[59]	SMP + SOF, 12	1	83; 83; NA	Yes
AI444040 Study group[60]	DCV + SOF, 24	2 or 3	100; NA; NA	No
	DCV + SOF + RBV, 24	2 or 3	86; NA; NA	No
	DCV + SOF, 24	1	100; NA; NA	Yes
	DCV + SOF + RBV, 24	1	95-100; NA; NA	Yes
ALLY-3 Study Team[61]	DCV + SOF, 12	3	86-91; 63; 96	Yes
ION-2 Investigators[62]	LDV + SOF, 12	1	94; 86; 97	Yes
	LDV + SOF, 24		99; 100; 99
	LDV + SOF + RBV, 12		96; 87; 100
	LDV + SOF + RBV, 24		99; 100; 99
ION-3 Investigators[63]	LDV + SOF, 8	1	94; NA; 94	No
	LDV + SOF + RBV, 8		93; NA; 93
	LDV + SOF, 12		95; NA; 95
MALACHITE-I/II[64]	OBV + PTV/r + DSV + RBV, 12	1	97-99; NA; 97-99	Yes
PEARL-I[65]	OBV + PTV/r	4	91; NA; 91	No
PEARL-I[65]	OBV + PTV/r + RBV	4	100; NA; 100	Yes
SAPPHIRE-II[66]	ABT-450/r + OBV + DSV + RBV, 12	1	96.3; NA; 93.6	Yes
TURQUOISE-II[67]	ABT-450/r + OBV + DSV + RBV, 12	1	91.8; 91.8; NA	Yes
TURQUOISE-II[67]	ABT-450/r + OBV + DSV + RBV, 24	1	95.9; 95.9; NA	Yes
ASTRAL-2 and ASTRAL-3[68]	SOF + VEL, 12	2	99; 100; 99	Yes
ASTRAL-2 and ASTRAL-3[68]	SOF + VEL, 12	3	95; 93; 98	Yes
C-WORTHY[69]	GZR + EBR, 12	1	91-97; 91-97; NA	Yes
	GZR + EBR + RBV, 12		90-94; 90-94; NA
	GZR + EBR, 18		94-97; NA; NA
	GZR + EBR + RBV, 18		97-100; NA; NA
Everson et al[70]	DCV + ASV + BCV, 12	1	88.8-89.5; 71.4-100; 87.5-91.1	No
Everson et al[70]	DCV + ASV + BCV + RBV, 12	1	85.7; 100; 85	No
SOUND-2[71]	FDV + deleobuvir + RBV, 16	1	59; NA; NA	No
	FDV + deleobuvir + RBV, 28		59-69; NA; NA
	FDV + deleobuvir + RBV, 40		52; NA; NA
	FDV + deleobuvir, 28		39; NA; NA

SVR: Sustained virological response; IFN: Interferon alfa; RBV: Ribavirin; PEG-IFN: Peginterferon alfa; TPV: Telaprevir; BOC: Boceprevir; SMP: Simeprevir; SOF: Sofosbuvir; DCV: Daclatasvir; LDV: Ledipasvir; OBV: Ombitasvir; PTV/r: Paritaprevir/ritonavir; DSV: Dasabuvir; VEL: Veltapasvir; GZR: Grazobuvir; EBR: Elbasvir; ASV: Asunaprevir; BCV: Beclabuvir; FDV: Faldaprevir.

Citation: Bastos JCS, Padilla MA, Caserta LC, Miotto N, Vigani AG, Arns CW. Hepatitis C virus: Promising discoveries and new treatments. World J Gastroenterol 2016; 22(28): 6393-6401
URL: https://www.wjgnet.com/1007-9327/full/v22/i28/6393.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i28.6393